Pharmac Consultation
- 2 hours ago
- 1 min read
Pharmac is seeking feedback on a proposal to widen access to three funded medicines for people with type 2 diabetes.Under the proposal, access to empagliflozin, liraglutide and dulaglutide would be widened so more people at high clinical risk can access these medicines earlier in their treatment. The proposal aims to support better long‑term management of diabetes and reduce the risk of serious heart and kidney complications.We are now inviting feedback on this proposal.
Consultation is open until 5pm, 28 May 2026. You can provide feedback by emailing consult@pharmac.govt.nz, or by using the online form linked in the consultation document.
Please feel free to share this consultation with others who may be interested.
Ngā mihi nui,
Pharmac | Te Pātaka Whaioranga | P: +0800 660 050| www.pharmac.govt.nz
